Facility Expansion and Infrastructure - The company has completed the construction of approximately 20,000 square meters of new facilities, enhancing operational capacity and supporting future business growth[2] - The company is expanding its production facilities, with plans to double its production capacity in the next 2-3 years[106] - The radioactive drug evaluation base in Wuxi is expected to be operational by mid-2023 after laboratory renovations and related qualifications are completed[112] - The company is constructing a leading radioactive drug evaluation center in Wuxi, expected to be operational in the second half of 2023[199] Financial Performance - The company reported a revenue of ¥2,267,970,979.11 for the period, representing a 49.54% increase compared to ¥1,516,680,031.67 in the previous year[61] - The company's net profit for the year 2022 was CNY 57,389.06 million, up from CNY 31,515.60 million in 2021, representing an increase of 82.00%[105] - The company reported a total revenue of 1.2 billion RMB for the year 2022, representing a year-over-year increase of 15%[174] - The company achieved a net cash flow from operating activities of ¥971,066,113.56, a 41.63% increase from ¥685,655,427.10 in the previous year[61] - The gross profit margin for the company's main business was 47.90%, a decrease of 0.83 percentage points year-on-year, with non-clinical research services at 48.31% and clinical services at 31.70%[62] - The gross profit margin improved to 45%, up from 40% in the previous year, due to operational efficiencies[181] - Basic earnings per share for 2022 increased to RMB 2.01, up 86.11% from RMB 1.08 in 2021[189] - Diluted earnings per share for 2022 reached RMB 2.00, reflecting an 86.92% increase compared to RMB 1.07 in 2021[189] - Net profit attributable to shareholders after deducting non-recurring gains and losses was RMB 576.504 million, a 63.62% increase from RMB 352.337 million in 2021[191] Market Growth and Trends - The Chinese CRO market is projected to grow from approximately USD 6.8 billion in 2019 to USD 22.2 billion by 2024, with a compound annual growth rate (CAGR) of about 26.5%[12] - The non-clinical safety evaluation market in China is expected to grow from USD 4.1 million in 2019 to USD 200 million by 2024, with a CAGR of 36.5%[12] - The Chinese experimental model market is projected to grow from approximately USD 400 million in 2019 to USD 1.5 billion by 2024, with a compound annual growth rate of about 28.1%[163] - Domestic orders from overseas clients increased by over 60%, indicating a strong trend in international market engagement[10] Research and Development - The company has made significant investments in digital infrastructure, with a full rollout of the quality management system (QMS) expected in 2023, aimed at improving service efficiency[5] - The company is focusing on developing specialized evaluation capabilities for innovative biopharmaceuticals, including ocular drugs and gene therapies, to create new competitive advantages[52] - The company is enhancing its capabilities in specialized drug delivery technologies, including ovarian and rectal administration[4] - The company is actively pursuing FDA and NMPA approvals for three new drug candidates, with expected submission dates in Q3 2023[182] - Investment in R&D increased by 25% in 2022, totaling 300 million RMB, focusing on innovative drug development technologies[177] - The company employed 2,127 R&D personnel, representing 76.3% of total employees, indicating a strong focus on research and development[92] Acquisitions and Strategic Partnerships - The company completed the acquisition of 100% equity in Guangxi Weimei Biotechnology Co., Ltd. for a total consideration of CNY 974,657,500, with CNY 925,924,600 paid by the end of 2022[97] - The company also acquired 100% equity in Yunnan Yingmao Biotechnology Co., Ltd. for CNY 829,307,100, with CNY 787,830,600 paid by the end of 2022[97] - The company invested CNY 500 million in JOINN Biologics Inc., acquiring 4.76% of its B+ round preferred shares[97] - A new strategic partnership was established with a leading biotech firm to enhance collaborative research efforts[179] - The company successfully completed the acquisition of a smaller CRO, which is expected to contribute an additional 200 million RMB in revenue annually[180] Operational Efficiency and Service Enhancement - The clinical services segment saw a substantial increase in new contracts and revenue, with a focus on comprehensive clinical operation services[5] - The company has established a comprehensive drug screening platform for preliminary evaluation of candidate molecules, enhancing customer engagement for subsequent pharmacological and toxicological assessments[35] - The company aims to enhance its non-clinical pharmacology and toxicology evaluation business as its core, steadily increasing market share and international influence[108] - The company is focusing on mergers and acquisitions to quickly establish R&D capabilities in areas where it lacks expertise[109] - The company is enhancing its non-clinical evaluation capabilities, focusing on innovative small molecule compounds and cardiac toxicity risks[200] Client Engagement and Market Presence - The number of active clients increased by 20% in 2022, reaching a total of 500 clients[175] - The company aims to expand its market presence by providing customized experimental model services and enhancing communication with clients[47] - The company plans to expand its market presence in Southeast Asia, targeting a 30% increase in market share by 2025[178] - The company will continue to enhance its international service capabilities and participate in global competition, aiming to establish itself as a comprehensive CRO with international competitiveness[108] Compliance and Certifications - The company has received multiple certifications, including GLP certification from CFDA (NMPA) and FDA, ensuring compliance with international standards for non-clinical safety evaluations[33] - The company has successfully passed GLP inspections from international regulatory bodies, enhancing its credibility and operational capabilities in the global market[33] - The company has received multiple GLP certifications from international regulatory bodies, including the FDA and OECD, enhancing its credibility in the industry[56] - The company has successfully passed multiple capability certifications, enhancing its service offerings in the clinical sample analysis field[161] Employee and Financial Management - Employee compensation increased by 63.27% to 125,638,153.76, accounting for 1.21% of total assets[73] - Tax payable rose by 165.53% to 62,968,764.75, representing 0.61% of total assets due to business growth[73] - Other payables surged by 257.71% to 199,531,750.44, making up 1.93% of total assets, primarily due to estimated acquisition payments[73] - Long-term borrowings decreased by 33.57% to 3,280,555.67, which is 0.03% of total assets, due to repayment of principal[73] - Deferred income increased by 32.59% to 80,676,206.51, representing 0.78% of total assets, mainly from large government subsidies received[73] - Deferred income tax liabilities rose by 288.71% to 188,243,430.39, accounting for 1.82% of total assets, due to new acquisitions[73]

Financial Performance - The company reported total revenue of RMB 2,267,971 thousand for the year ended December 31, 2022, representing an increase from RMB 1,516,680 thousand in 2021, which is a growth of 49.5%[2] - Gross profit for the year was RMB 1,081,428 thousand, compared to RMB 1,516,680 thousand in the previous year, reflecting a decrease of 49.5%[2] - Net profit for the year reached RMB 1,073,200 thousand, a significant increase of 47.0% from RMB 735,678 thousand in 2021[2] - Profit attributable to equity shareholders of the company was RMB 1,074,257 thousand, up 92.9% from RMB 556,417 thousand in the prior year[2] - The reported revenue for 2022 was RMB 2,703,608,000, with a gross profit of RMB 1,074,938,000[16] - The gross profit for the reportable segments in 2022 was RMB 1,074,938,000, compared to RMB 749,555,000 in 2021[19] - The net profit for the year ended December 31, 2022, increased by 92.9% to RMB 1,073.2 million, with a net profit margin rising to 47.3% from 36.7%[66] Assets and Liabilities - The company's total assets amounted to RMB 8,519,954 thousand as of December 31, 2022, compared to RMB 7,322,835 thousand in 2021, indicating a growth of 16.4%[5] - The net asset value attributable to equity shareholders was RMB 8,183,701 thousand, reflecting an increase of 14.7% from RMB 7,136,214 thousand in the previous year[2] - The equity-to-debt ratio as of December 31, 2022, was 21.0%, up from 16.3% at the end of 2021[69] - As of December 31, 2022, the group had no significant contingent liabilities or major asset pledges[92] Cash Flow and Dividends - The company’s cash and cash equivalents stood at RMB 2,916,848 thousand, up from RMB 680,978 thousand in 2021, indicating a strong liquidity position[5] - The proposed final dividend for 2022 is RMB 0.40 per share, an increase from RMB 0.36 per share in 2021, totaling RMB 214,258,000 for the year[31] - The total cash dividend paid for the previous fiscal year was RMB 137,363,000, compared to RMB 94,850,000 in 2021, indicating a growth of approximately 45%[32] Research and Development - The company reported a significant increase in research and development expenses, which were RMB 299,873 thousand, compared to RMB 264,321 thousand in the previous year[3] - Research and development expenses for the year ended December 31, 2022, were RMB 78.0 million, a 63.3% increase from RMB 47.8 million in the previous year[63] Market and Revenue Segmentation - Non-clinical research services generated revenue of RMB 2,213.598 million in 2022, while clinical trial and related services accounted for RMB 49.568 million[12] - The total amount of unfulfilled contract revenue as of December 31, 2022, was approximately RMB 4,400 million, up from RMB 2,900 million in 2021, indicating a growth of 51.7%[12] - The company does not derive more than 10% of its total revenue from any single customer[12] - The group operates three reportable segments: non-clinical research services, clinical trial and related services, and sales of experimental models[13] Employee and Operational Growth - The company reported a significant increase in employee costs, totaling RMB 558,665,000 in 2022 compared to RMB 427,838,000 in 2021[23] - The company expanded its professional service team to over 2,700 members by the end of 2022, an increase of nearly 650 personnel compared to the end of 2021[40] - The company completed the construction of over 20,000 square meters of new facilities, enhancing its operational capacity to ensure smooth order delivery[41] Strategic Initiatives and Future Plans - The company plans to continue expanding its market presence and investing in new product development to drive future growth[2] - The management anticipates that the majority of the unfulfilled contract revenue will be recognized within three years from the reporting date[12] - The company aims to become a leading international clinical testing platform, providing one-stop clinical trial sample testing services for innovative drug products[48] - The company plans to issue 4 new shares for every 10 existing shares to eligible shareholders, pending approval at the annual general meeting[31] Acquisitions and Investments - The company completed the acquisition of 100% equity in Guangxi Weimei for RMB 974,658,000, focusing on breeding and selling experimental models[87] - The company also acquired 100% equity in Yunnan Yingmao for RMB 829,307,000, which is involved in similar business activities as Guangxi Weimei[87] - The company has committed RMB 1,057.0 million for potential acquisitions focused on non-clinical and clinical research organizations, with a completion target set for 2024[85] Compliance and Audit - The audit committee has reviewed the consolidated annual performance for the year ended December 31, 2022, and confirmed compliance with relevant accounting standards and regulations[97] - The group's auditor, KPMG, has agreed that the financial figures in the preliminary announcement align with the audited consolidated financial statements for the year ended December 31, 2022[98]

证券代码：603127 证券简称：昭衍新药 公告编号：2023-007 会议召开时间：2023 年 04 月 04 日(星期二) 下午 15:00-16:00 会议召开地点： 上海证券 交易所上证路演中心（ 网 址 ： http://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络互动 北京昭衍新药研究中心股份有限公司 关于召开 2022 年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 投资者可于 2023 年 03 月 28 日(星期二) 至 04 月 03 日(星期一)16:00 前登 录上证路演中心网站首页点击"提问预征集"栏目或通过公司投资者关系邮箱： jiafengsong@joinn-lab.com 进行提问。公司将在说明会上对投资者普遍关注的 问题进行回答。 北京昭衍新药研究中心股份有限公司（以下简称"公司"）将于 2023 年 3 月 31 日发布公司 2022 年度报告，为便于广大投资者更全面深入地了解公司 2022 年度经营成果、财务状 ...

Financial Performance - The company's operating revenue for Q3 2022 was RMB 499,511,815.43, representing a year-on-year increase of 55.01%[2] - The net profit attributable to shareholders for the same period was RMB 260,913,556.78, showing a significant increase of 176.77% year-on-year[2] - The net profit attributable to shareholders after deducting non-recurring gains and losses reached RMB 260,340,236.28, up 195.97% compared to the previous year[2] - The basic earnings per share for Q3 2022 was RMB 0.49, an increase of 88.46% year-on-year[4] - The company's revenue for the current reporting period increased by 55.01%, primarily due to business growth[11] - The net profit attributable to shareholders for the current reporting period rose by 176.77%, driven by business growth and the appreciation of biological assets[11] - The net profit attributable to shareholders after deducting non-recurring gains and losses increased by 195.97% in the current reporting period, attributed to business growth and biological asset appreciation[11] - The basic earnings per share for the current reporting period reached 88.46 RMB, reflecting significant business growth[11] - The net profit for Q3 2022 was approximately CNY 630.97 million, a significant increase from CNY 247.01 million in Q3 2021, representing a growth of 155.5%[21] - The total revenue from operating activities for the first three quarters of 2022 reached CNY 1.98 billion, compared to CNY 1.39 billion in the same period of 2021, indicating a year-over-year increase of 42.5%[23] - The operating profit for Q3 2022 was CNY 717.78 million, up from CNY 281.54 million in Q3 2021, marking a growth of 154.1%[21] - The total comprehensive income for Q3 2022 was CNY 666.16 million, compared to CNY 245.57 million in Q3 2021, which is an increase of 171.5%[22] - Basic earnings per share for Q3 2022 were CNY 1.18, up from CNY 0.68 in Q3 2021, representing a growth of 73.5%[22] Cash Flow and Assets - The net cash flow from operating activities for the year-to-date was RMB 778,288,380.46, representing a 67.93% increase year-on-year[2] - The cash flow from operating activities for Q3 2022 was CNY 778.29 million, compared to CNY 463.45 million in Q3 2021, reflecting an increase of 77.5%[24] - The company's cash and cash equivalents decreased from approximately 4.15 billion RMB at the end of 2021 to about 2.87 billion RMB by September 30, 2022[15] - The cash and cash equivalents at the end of Q3 2022 were CNY 2.85 billion, down from CNY 4.11 billion at the end of Q3 2021, a decrease of 30.5%[25] - The net cash flow from investing activities for Q3 2022 was negative CNY 2.03 billion, compared to negative CNY 1.89 billion in Q3 2021, indicating a worsening of cash outflow[24] Assets and Liabilities - The total assets at the end of the reporting period amounted to RMB 10,079,078,937.04, reflecting an 18.06% increase from the end of the previous year[4] - The company's total assets as of the end of the third quarter of 2022 were ¥10,079,078,937.04, an increase from ¥8,537,077,111.40 at the end of the previous year, representing a growth of about 18%[18] - Total liabilities increased to ¥2,408,488,539.00 in the third quarter of 2022, compared to ¥1,392,640,954.56 in the same period last year, marking an increase of approximately 73%[18] - The company's total equity reached ¥7,670,590,398.04, up from ¥7,144,436,156.84 in the previous year, indicating a growth of about 7.4%[18] Research and Development - Research and development expenses for the first three quarters of 2022 amounted to ¥50,053,890.87, up from ¥35,019,894.79 in 2021, reflecting a growth of approximately 43%[20] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 37,275[12] - The largest shareholder, Feng Yuxia, holds 22.31% of the shares[13] Government Subsidies and Acquisitions - The government subsidies received during the year-to-date amounted to RMB 8,457,000, down from RMB 23,608,000 in the same period last year[5] - The company has made acquisitions of Yunnan Yingmao Biotechnology Co., Ltd. and Guangxi Weimei Biotechnology Co., Ltd., resulting in a negative goodwill of RMB 14,367,000[5] Market Outlook - The company has over 4.6 billion RMB in hand orders as of the reporting period, providing strong support for future performance growth[14] - The company plans to expand its market presence and invest in new technologies, although detailed strategies were not specified in the report[20]

Financial Performance - The company's operating revenue for the third quarter was RMB 499,511,815.43, representing a year-on-year increase of 55.01%[4] - Net profit attributable to shareholders for the third quarter was RMB 260,913,556.78, showing a significant year-on-year growth of 176.77%[4] - The net profit attributable to shareholders after deducting non-recurring gains and losses reached RMB 260,340,236.28, with a year-on-year increase of 195.97%[4] - The basic earnings per share for the third quarter was RMB 0.49, an increase of 88.46% compared to the same period last year[5] - The diluted earnings per share for the third quarter was RMB 0.49, with an increase of 88.46% compared to the same period last year[5] - The company reported a net profit attributable to shareholders for the year-to-date of 154.85%, driven by business growth and increased financial income[11] - Diluted earnings per share for the year-to-date increased by 76.12%, due to business growth and increased financial income[12] - Total revenue for the first three quarters of 2022 reached ¥1,276,392,981.45, a significant increase from ¥856,804,399.15 in the same period of 2021, representing a growth of approximately 49%[22] - Net profit attributable to shareholders of the parent company for the first three quarters of 2022 was ¥632,033,151.04, up from ¥248,006,161.31 in 2021, reflecting a growth of approximately 154%[24] - Basic earnings per share for the first three quarters of 2022 were ¥1.18, compared to ¥0.68 in the same period of 2021, marking an increase of about 74%[25] Cash Flow and Assets - The net cash flow from operating activities for the year-to-date was RMB 778,288,380.46, representing a year-on-year increase of 67.93%[4] - Cash flow from operating activities for the year-to-date increased by 67.93%, due to increased sales collections and interest income[11] - Cash inflow from operating activities in the first three quarters of 2022 was ¥2,085,281,684.08, compared to ¥1,422,490,961.55 in 2021, showing an increase of approximately 47%[28] - The total assets at the end of the reporting period amounted to RMB 10,079,078,937.04, reflecting an increase of 18.06% from the end of the previous year[5] - Current assets totaled approximately 5.72 billion RMB, slightly down from 5.81 billion RMB at the end of 2021, indicating a decrease of about 1.2%[18] - The company's cash and cash equivalents were reported at approximately 2.87 billion RMB, down from 4.15 billion RMB at the end of 2021, a decline of about 30.8%[17] - The total cash and cash equivalents at the end of the third quarter of 2022 were approximately 2.85 billion, down from 4.11 billion at the end of the same period in 2021[31] - The company reported a net increase in cash and cash equivalents of approximately -1.30 billion in the first three quarters of 2022, compared to an increase of 3.81 billion in the same period of 2021[31] Liabilities and Equity - The total liabilities increased to approximately 2.41 billion RMB from 1.39 billion RMB, representing a growth of about 73.5%[20] - The company's equity attributable to shareholders rose to approximately 7.66 billion RMB, compared to 7.14 billion RMB at the end of 2021, an increase of about 7.4%[20] Inventory and Investments - The company reported a significant increase in inventory, which rose to approximately 2.21 billion RMB from 700.59 million RMB, a growth of about 215.5%[18] - The long-term investments decreased slightly to approximately 23.66 million RMB from 25.29 million RMB, a decline of about 6.5%[18] - The company experienced a decrease in investment income from joint ventures and associates, reporting a loss of ¥1,632,476.09 in the first three quarters of 2022[23] Operational Highlights - The company has secured a strong order backlog of over 4.6 billion RMB, ensuring robust future revenue growth[16] - The company has implemented effective measures to ensure the smooth delivery of orders, which is expected to positively impact future performance[16] - The company is focusing on new product development and market expansion strategies to enhance its competitive position in the industry[16] Research and Development - Research and development expenses for the first three quarters of 2022 amounted to ¥50,053,890.87, up from ¥35,019,894.79 in 2021, indicating a growth of about 43%[22] Other Financial Metrics - The company reported a loss of RMB 4,880,000 from the valuation changes of trading financial assets during the year-to-date[6] - The company recognized government subsidies amounting to RMB 8,457,000 for the year-to-date, compared to RMB 2,361,000 in the same period last year[7] - The company recorded a net loss of -3,089,926.69 from fair value changes in financial assets and liabilities[10] - The company has not defined any non-recurring gains and losses as recurring gains and losses[10] - Other comprehensive income after tax for the first three quarters of 2022 was ¥35,188,864.58, compared to -¥1,441,837.91 in 2021, indicating a positive turnaround[24]

Financial Performance - JOINN Laboratories reported a revenue of 83 million RMB for the first half of 2022, reflecting a significant growth compared to the previous period[1]. - Revenue for the six months ended June 30, 2022, was RMB 776,881 thousand, representing a 45.3% increase compared to RMB 534,556 thousand in 2021[27]. - Gross profit for the same period was RMB 377,942 thousand, up 40.7% from RMB 268,571 thousand in 2021[27]. - Net profit for the period reached RMB 370,384 thousand, a significant increase of 141.9% from RMB 153,093 thousand in 2021[27]. - Basic earnings per share increased by 125.6% to RMB 0.97 from RMB 0.43 in the previous year[27]. - Total comprehensive income for the period was RMB 388,471 thousand, compared to RMB 150,725 thousand, reflecting a growth of 157.5%[122]. - The company reported a net profit of RMB 371,120 thousand for the six months ended June 30, 2022, compared to RMB 153,735 thousand for the same period in 2021, representing a significant increase[128]. - Cash generated from operating activities for the six months ended June 30, 2022, was RMB 545,494 thousand, compared to RMB 202,465 thousand for the same period in 2021, reflecting improved operational efficiency[131]. Growth and Expansion - The company has expanded its user base, with a 25% increase in clients year-over-year, indicating strong demand for its services[1]. - JOINN Laboratories projects a revenue growth of 15% for the next fiscal year, driven by new product launches and market expansion strategies[1]. - JOINN Laboratories aims to enter the Southeast Asian market by the end of 2023, which is expected to increase its market share significantly[1]. - The company is exploring potential acquisitions to enhance its market position, targeting companies with complementary services[1]. - The company has established strategic partnerships with three major pharmaceutical companies to enhance its service offerings[1]. - The company plans to establish a drug safety evaluation center in Guangzhou and a GLP-compliant non-clinical research laboratory in Chongqing, with operations expected to start in 2023[57]. - The company aims to enhance its global footprint and service capabilities, leveraging the strategic acquisition of Biomere to expand its presence in the North American pharmaceutical market[57]. Research and Development - The company is investing heavily in R&D, with a budget allocation of 20 million RMB for the development of new technologies and products in the upcoming year[1]. - The company is committed to ensuring stable operations and sustainable development in the future[29]. - The company has optimized various drug evaluation models, including those for ophthalmic and otologic drugs, enhancing its technical capabilities[35]. - The company is actively participating in a national project for the research of a new DNA vaccine platform, which received approval in the first half of 2022[35]. - The company has created over 30 disease animal models for preclinical drug efficacy evaluation, with plans to expand production capacity[38]. Operational Efficiency - The company reported a 30% increase in operational efficiency due to the implementation of new technologies in its laboratories[1]. - The company plans to integrate industry resources and deploy new business capabilities and service models to enhance operational efficiency[29]. - The company has established a wholly-owned subsidiary, Beijing Zhaoyan Drug Testing Research Co., Ltd., to enhance its cell testing business and support innovative drug development[37]. Financial Position - Total assets as of June 30, 2022, were RMB 10,646,728 thousand, reflecting a 24.7% increase from RMB 8,537,077 thousand at the end of 2021[28]. - Total liabilities increased by 132.7% to RMB 3,240,946 thousand from RMB 1,392,641 thousand in 2021[28]. - The company maintained a stable capital structure with a debt-to-equity ratio of 0.1% as of June 30, 2022, unchanged from December 31, 2021[52]. - As of June 30, 2022, cash and cash equivalents were RMB 3,801.0 million, a decrease of 8.5% from RMB 4,154.1 million at the end of 2021[51]. Employee and Shareholder Information - Employee costs totaled approximately RMB 303.0 million, up from RMB 212.7 million in the same period last year[56]. - The company has expanded its professional service team to over 2,600 members, an increase of nearly 500 from the end of 2021[31]. - The board does not recommend the payment of an interim dividend for the six months ended June 30, 2022[62]. - The company has granted a total of 3,785,000 stock options under various incentive plans, with an average exercise price of RMB 59.49 as of June 30, 2022[193]. Market Performance - The total order amount as of June 30, 2022, reached over RMB 4.1 billion, providing a solid foundation for future performance[39]. - The company signed orders exceeding RMB 2 billion in overseas markets, with a year-on-year growth of nearly 30%[41]. - The marketing efforts in the first half of 2022 resulted in over RMB 20 billion in signed orders, with domestic orders exceeding RMB 18 billion, a year-on-year increase of over 50%[40]. Sustainability and Corporate Governance - JOINN Laboratories is committed to sustainability, with plans to reduce its carbon footprint by 25% over the next five years[1]. - The company has adopted corporate governance principles and has complied with applicable code provisions during the six months ending June 30, 2022[110]. - There have been no significant litigation or arbitration cases from the listing date to June 30, 2022[112].

Financial Performance - The company reported a total revenue of 1.2 billion RMB for the first half of 2022, representing a year-on-year increase of 15%[4]. - The net profit attributable to shareholders for the same period was 300 million RMB, up 20% compared to the previous year[4]. - The company's operating revenue for the first half of 2022 reached RMB 776,881,166.02, representing a 45.33% increase compared to RMB 534,556,471.63 in the same period last year[15]. - The net profit attributable to shareholders for the first half of 2022 was RMB 371,119,594.26, a significant increase of 141.40% from RMB 153,734,926.32 in the previous year[15]. - The net cash flow from operating activities for the first half of 2022 was RMB 545,493,427.60, which is a 169.43% increase from RMB 202,465,705.85 in the previous year[15]. - Future guidance indicates a revenue growth target of 20% for the full year 2022[4]. - The total order amount on hand reached over 4.1 billion RMB, providing a solid foundation for future performance[57]. Market Expansion and Strategy - The company plans to expand its market presence in Southeast Asia, targeting a 10% market share by the end of 2023[4]. - The company has no plans for mergers or acquisitions in the near term, focusing instead on organic growth strategies[4]. - The company is focusing on expanding its market presence in the CRO and experimental model sectors, driven by increasing domestic and international demand[25]. Research and Development - The company has allocated 200 million RMB for R&D in 2022, a 30% increase from the previous year[4]. - New product development includes a pipeline of 5 innovative drugs expected to enter clinical trials by Q4 2022[4]. - The company is developing a leading genetic resource and gene engineering technology platform for creating animal disease models for new drug development[34]. - The company has established a comprehensive drug screening platform for both in vitro and in vivo evaluations, improving the efficiency of drug development[46]. Financial Position - The total assets of the company at the end of the reporting period amounted to RMB 10,646,728,994.36, marking a 24.71% increase from RMB 8,537,077,111.40 at the end of the previous year[15]. - The net assets attributable to shareholders at the end of the reporting period were RMB 7,398,296,481.53, showing a 3.67% increase from RMB 7,136,214,378.04 at the end of the previous year[15]. - The company's cash and cash equivalents at the end of the period amounted to ¥3,800,990,974.43, representing 35.69% of total assets, a decrease of 8.50% compared to the previous year[62]. - The company reported a substantial increase in productive biological assets, which reached ¥777,775,918.46, a 949.42% increase due to acquisitions and fair value adjustments[63]. Risk Management - The management highlighted potential risks related to regulatory changes and market competition[4]. - The company faces risks related to international economic fluctuations, which may negatively impact the pharmaceutical industry and drug innovation investments due to the ongoing COVID-19 pandemic[73]. Environmental Commitment - The company emphasized its commitment to environmental protection and sustainable development, implementing a comprehensive environmental management system[83]. - The company plans to continue investing in environmental improvements to ensure compliance with pollution discharge standards[83]. - The company ensures compliance with environmental standards, including wastewater discharge limits and air pollutant emission standards, through regular third-party inspections and treatment processes[88]. Shareholder Information - The company granted 675,400 restricted A shares to 505 incentive recipients as part of its equity incentive plan approved on January 28, 2022[80]. - The company distributed cash dividends of 0.36 yuan per share and increased capital reserves by 0.4 shares per share, resulting in a total share capital of 534,191,429 shares[103]. - The largest shareholder, Feng Yuxia, held 85,286,037 shares, representing 22.35% of the total shares[105]. Compliance and Governance - The company has committed to not engaging in any competitive business activities with its controlling shareholders and related parties, ensuring no conflicts of interest[91]. - There were no non-operational fund occupations or guarantee violations reported during the reporting period[96]. - The financial statements comply with the requirements of the enterprise accounting standards, reflecting the company's financial position and operating results accurately[141].

2022 年第一季度报告 单位：元币种：人民币 证券代码：603127 证券简称：昭衍新药 北京昭衍新药研究中心股份有限公司 2022 年第一季度报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整，不存 在虚假记载、误导性陈述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务报表 信息的真实、准确、完整。 第一季度财务报表是否经审计 □是 √否 一、 主要财务数据 (一)主要会计数据和财务指标 | --- | --- | --- | |-----------------------------------------------|----------------|-------------------------------------| | 项目 | 本报告期 | 本报告期比上年同期增减 变动幅度 (%) | | 营业收入 | 270,975,486.87 ...

Financial Performance - The company's operating revenue for Q1 2022 was RMB 270,975,486.87, representing a year-on-year increase of 34.82%[3] - Net profit attributable to shareholders for the same period was RMB 125,347,354.57, reflecting a growth of 34.27% year-on-year[3] - The net profit attributable to shareholders after deducting non-recurring gains and losses increased by 66.65% year-on-year, amounting to RMB 132,381,980.64[3] - Basic earnings per share for the quarter were RMB 0.33, up 17.86% year-on-year[3] - The company reported a significant increase in cash inflow from investment activities compared to the previous year, indicating a positive trend in investment returns[27] Cash Flow - The net cash flow from operating activities reached RMB 74,906,349.49, a significant increase of 117.23% compared to the previous year[3] - Cash inflow from investment activities totaled approximately $334.48 million, with a net cash inflow from investment activities of about $72.50 million[27] - The cash flow from operating activities generated a net amount of CNY 74,906,349.49 in Q1 2022, compared to CNY 34,482,082.76 in Q1 2021, indicating a growth of 117.5%[26] - The cash flow from investment activities showed a substantial improvement compared to the previous year's negative cash flow of approximately $66.69 million[27] - The company’s cash position remains strong, with a significant balance of cash and cash equivalents at the end of the reporting period[28] Assets and Liabilities - Total assets at the end of the reporting period were RMB 8,957,151,364.84, an increase of 4.92% from the end of the previous year[4] - Total current assets increased to CNY 6,186,990,976.77 as of March 31, 2022, compared to CNY 5,814,484,316.60 at the end of 2021, representing a growth of 6.4%[14] - Non-current assets totaled CNY 2,770,160,388.07 as of March 31, 2022, slightly up from CNY 2,722,592,794.80 at the end of 2021[15] - Total liabilities increased to CNY 1,685,280,811.53 as of March 31, 2022, compared to CNY 1,392,640,954.56 at the end of 2021, indicating a rise of 20.9%[16] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 31,729[10] - The top shareholder, Feng Yuxia, holds 89,702,855 shares, accounting for 23.51% of total shares[10] Business Growth - New orders signed exceeded 1 billion RMB, representing a year-on-year growth of over 65%[12] - The total amount of orders on hand reached over 3.6 billion RMB at the end of the reporting period[12] - Operating revenue increased by 34.82% due to business growth[9] - Net profit attributable to shareholders increased by 34.27% driven by business expansion[9] - Net profit attributable to shareholders after deducting non-recurring gains and losses rose by 66.65% as a result of business growth[9] Research and Development - Research and development expenses increased to CNY 12,289,064.34 in Q1 2022, compared to CNY 9,878,808.23 in Q1 2021, reflecting a growth of 24.3%[19] - Future outlook includes continued investment in R&D to drive innovation and market expansion strategies[19] Other Financial Metrics - The company reported a fair value loss of RMB 14,472,000 related to trading financial assets, impacting net profit[5] - The unrealized gain from biological assets was RMB 34,494,000, contributing positively to net profit[6] - The company received government subsidies amounting to RMB 2,580,000 during the reporting period[5] - The weighted average return on net assets decreased by 1.34 percentage points due to the full weighting of net assets raised from the Hong Kong stock issuance[9] - The company's total profit for Q1 2022 was CNY 139,756,935.47, up from CNY 104,035,964.94 in Q1 2021, reflecting an increase of 34.4%[20]

Financial Performance - JOINN Laboratories reported a revenue of RMB 1.2 billion for the fiscal year 2021, representing a year-over-year growth of 25%[6]. - The company achieved a net profit of RMB 300 million, which is an increase of 30% compared to the previous year[6]. - Total revenue for 2021 reached RMB 1,516,680,000, a 40.9% increase from RMB 1,075,905,000 in 2020[14]. - Gross profit for 2021 was RMB 735,678,000, resulting in a gross margin of 48.51%[14]. - Net profit attributable to equity shareholders for 2021 was RMB 557,460,000, up from RMB 312,950,000 in 2020, reflecting an increase of 78.5%[14]. - Basic earnings per share for 2021 were RMB 1.51, compared to RMB 0.99 in 2020, representing a 52.5% increase[14]. - The company reported a gross margin of 45%, which is an improvement from 42% in the previous year[6]. - In 2021, the company achieved a revenue growth of approximately 41% year-on-year, with net profit attributable to equity shareholders increasing by about 78%[16]. - The company reported a profit distribution plan for the year ending December 31, 2021, proposing a final dividend of RMB 0.36 per share, up from RMB 0.35 in 2020[73]. - The total amount of the proposed final dividend is approximately RMB 137,248,000, compared to RMB 94,850,000 in 2020[73]. Market Expansion and Strategy - JOINN Laboratories plans to expand its market presence in Europe and North America, targeting a 20% increase in international revenue by 2023[6]. - The company plans to continue expanding its market presence and investing in new product development[12]. - The company aims to enhance its global footprint and service capabilities, leveraging the strategic acquisition of Biomere to upgrade facilities and expand services in the North American pharmaceutical market[48]. - The company is focusing on strategic partnerships with leading pharmaceutical companies to enhance its service offerings[6]. - The company plans to invest in expanding its clinical trial services and strengthen its scientific and regulatory teams to support clinical trial operations[48]. Research and Development - The company is investing RMB 200 million in R&D for new drug development technologies, aiming to launch two new products by the end of 2022[6]. - Research and development efforts are focused on innovative drug discovery and enhancing drug metabolism studies[11]. - The company has established a comprehensive platform for non-clinical evaluation, focusing on innovative drug research and evaluation capabilities across various new technologies and targets[19]. - The company successfully created gene-edited cell lines and animal models for rare disease drug development, enhancing its innovative drug research capabilities[22]. Operational Efficiency - JOINN Laboratories is implementing new operational strategies to improve efficiency, aiming for a 10% reduction in operational costs by 2023[6]. - The company upgraded its laboratory information management system (LIMS) and introduced new document management and employee training systems to enhance operational efficiency[19]. - The company expanded its workforce to over 2,100 professionals by December 31, 2021, enhancing the capabilities of its non-clinical research service team[17]. Acquisitions and Partnerships - JOINN Laboratories has completed the acquisition of Biomedical Research Models, Inc., enhancing its capabilities in preclinical research[6]. - The company is exploring potential mergers and acquisitions to strengthen its market position and capabilities[12]. - The company aims to selectively pursue acquisitions of businesses and assets that complement its growth strategy, particularly in non-clinical research and drug discovery services[52]. Financial Position and Assets - Total assets as of December 31, 2021, amounted to RMB 8,537,077,000, significantly higher than RMB 2,172,902,000 in 2017[15]. - Total liabilities for 2021 were RMB 1,392,641,000, compared to RMB 951,093,000 in 2020[15]. - Net assets for 2021 stood at RMB 7,144,436,000, an increase from RMB 1,221,809,000 in 2017[15]. - Cash and cash equivalents as of December 31, 2021, were RMB 41,541 million, an increase of 1,245.7% from RMB 3,087 million as of December 31, 2020[43]. Risks and Challenges - The company faces regulatory compliance risks due to the need to adhere to multiple laws and regulations across different countries, which could adversely affect its reputation and financial performance[53]. - Talent recruitment risks are heightened as the company expands, necessitating the cultivation and introduction of skilled personnel to meet current and future business needs[54]. - Market competition risks are increasing as competitors expand capacity and facilities, necessitating the company to maintain its core competitive advantages[55]. - The ongoing COVID-19 pandemic poses challenges to daily operations, and future developments in the pandemic could impact business operations depending on national policies[59]. Corporate Governance - The board consists of 10 members, with executive directors having service contracts established in February 2021 for an initial term of three years[83]. - The company has established a framework for maintaining shareholder interests and enhancing corporate value through effective governance practices[152]. - The board of directors held seven meetings during the reporting period, exceeding the minimum requirement of four meetings per year[175]. - The company has adopted a board nomination policy outlining criteria for selecting candidates for appointment or reappointment[166]. Shareholder Relations - The company emphasizes the importance of effective communication with shareholders to enhance investor relations[195]. - Shareholders holding more than 3% of the company's shares can propose temporary motions at least 10 days before the annual general meeting[193]. - The company has established a policy to maintain communication with shareholders, ensuring timely responses to shareholder concerns and suggestions[195]. Employee and Labor Relations - The company has established a union in China to represent employees and ensure compliance with labor laws and regulations[138]. - The employer matches employee contributions to the 401(k) plan up to 4% of eligible wages, providing a safety net for retirement savings[141]. Environmental and Social Responsibility - The company has established detailed internal rules for environmental protection, with no additional costs incurred for compliance as of December 31, 2021[74]. - The company emphasizes compliance with anti-bribery and anti-corruption regulations to mitigate risks associated with bribery and corruption[138]. - The company made donations amounting to RMB 1.2 million during the reporting period[151].